Those who plot the destruction of others often fall themselves. [Lat., Saepe intereunt aliis meditantes necem.]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$EPAZ Epazz Inc. is an enterprise-wide software company specializing in providing customized Web applications to the corporate world, higher education institutions, and the public sector.
Epazz’ unique BoxesOS applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce all through the medium of the Internet.
Epazz was founded by Shaun Passley in February 1999 who saw the need and benefits of integrated Web-based applications for the increasing demand of relevant and timely information for personal and business management. Today his vision has expanded to include the business world and the public sector as well as higher education institutions
$PLPL on ALERT, way overdue to run, imo !!
Hopefully we get some EPAZ news !
$EPAZ looking to turn a profit today !!
$EPAZ on ALERT ! volume comes in early this can go !!
Like to see PLPL pick it up !!
Check out $EPAZ www.Epazz.com
$EPAZ looking to make a move today !
$EPAZ on ALERT...due to run !
Good morning EPAZ !
Good morning PLPL !
Good morning Everyone !
PLPL has good bid support, holding a gain...nice to see it finally !!
PLPL doing well today, nice buying going on !
PLPL still holding green today, Good sign !!
Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko Phytofare Factory
Factory Set to Commence Operating in April 2014
SEATTLE, WA--(Marketwired - Apr 1, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has completed and successfully optimized Stage 2 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa. Section 2 is the critical stage of the factory's operations as it is in this section that the hydrodynamic sheering process takes place.
As previously disclosed, Plandaí's unique extraction system uses live plant material and a combination of temperature and a unique wave of acoustic energy to release the living phytonutrients, rearranging the polyenes into a bio-compatible form. Stage 3 of the process then separates out the solids and any unnecessary elements, rendering pharmaceutical-grade, purified catechins in mainly nano-particle form. This Phytofareâ„¢ Catechin complex can then be sold "as is" as an ingredient for nutraceuticals and cosmetics or further processed by incorporating it into a Pheroid® emulsion. The Pheroidâ„¢ serves to protect the Phytofareâ„¢ as it passes through the GI tract or can enhance topical absorption.
Plandaí's engineering team is currently working to complete Stage 3 and supporting infrastructures, including the boiler and computer automation system, which should brought online during April 2014. The final commissioning will take place this month as the company's engineers and scientists fine-tune the equipment, train staff, and test the output for conformity with the product profile.
Chairman and Chief Executive Officer Roger Duffield commented, "Having successfully commissioned Stage 2, the one of a kind system is now complete. The magic of Phytofare involves unzipping the molecule to release the valuable phytonutrients, which we have now done for the first time on an industrial scale. Stage 3 should shortly come online once the computer system is in place and the final pieces are connected. It is exciting to see the culmination of over ten years of research and effort on the part of countless supporters."
The first product Plandaí will bring to the market is Phytofareâ„¢ Catechin Complex, which includes the entire catechin profile derived from green tea. Stages 2 and 3 are also set up to process lemons, which will lead to the introduction of Phytofareâ„¢ Limonoid Glycoside Complex later in the year. Citrus bioflavonoids are highly regarded not only for treating cold and flu symptoms but also as a potent anti-inflammatory useful for soft-tissue injuries and sports recovery.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofareâ„¢ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Contact:
Andrew Beyer
Phone: Toll Free 888-627-6902
Email: investor@Plandaíbiotech.com
Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko Phytofare Factory
Factory Set to Commence Operating in April 2014
SEATTLE, WA--(Marketwired - Apr 1, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has completed and successfully optimized Stage 2 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa. Section 2 is the critical stage of the factory's operations as it is in this section that the hydrodynamic sheering process takes place.
As previously disclosed, Plandaí's unique extraction system uses live plant material and a combination of temperature and a unique wave of acoustic energy to release the living phytonutrients, rearranging the polyenes into a bio-compatible form. Stage 3 of the process then separates out the solids and any unnecessary elements, rendering pharmaceutical-grade, purified catechins in mainly nano-particle form. This Phytofareâ„¢ Catechin complex can then be sold "as is" as an ingredient for nutraceuticals and cosmetics or further processed by incorporating it into a Pheroid® emulsion. The Pheroidâ„¢ serves to protect the Phytofareâ„¢ as it passes through the GI tract or can enhance topical absorption.
Plandaí's engineering team is currently working to complete Stage 3 and supporting infrastructures, including the boiler and computer automation system, which should brought online during April 2014. The final commissioning will take place this month as the company's engineers and scientists fine-tune the equipment, train staff, and test the output for conformity with the product profile.
Chairman and Chief Executive Officer Roger Duffield commented, "Having successfully commissioned Stage 2, the one of a kind system is now complete. The magic of Phytofare involves unzipping the molecule to release the valuable phytonutrients, which we have now done for the first time on an industrial scale. Stage 3 should shortly come online once the computer system is in place and the final pieces are connected. It is exciting to see the culmination of over ten years of research and effort on the part of countless supporters."
The first product Plandaí will bring to the market is Phytofareâ„¢ Catechin Complex, which includes the entire catechin profile derived from green tea. Stages 2 and 3 are also set up to process lemons, which will lead to the introduction of Phytofareâ„¢ Limonoid Glycoside Complex later in the year. Citrus bioflavonoids are highly regarded not only for treating cold and flu symptoms but also as a potent anti-inflammatory useful for soft-tissue injuries and sports recovery.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofareâ„¢ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Contact:
Andrew Beyer
Phone: Toll Free 888-627-6902
Email: investor@Plandaíbiotech.com
PLPL up almost 5% !!
Agreed, PLPL will definitely have it's time soon !!
PLPL off to a great start !!
PLPL on ALERT !! overdue for a big move...
Good morning PLPL !
When PLPL breaksout, it's going to be big...Stay tuned !!!
Nice bounce ! whoever got those at .98 going to get paid this week !!
Plandai Biotechnology "Waiver" Could Dramatically Expedite Medical Marijuana Research
NEW YORK, NY--(Marketwired - Mar 31, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) has a real opportunity to advance its medical marijuana research, and in doing so, it could be one of the first publicly traded companies in the cannabis industry to reach clinical trials with the drug. While laws in the US still prohibit the advancement of research using marijuana due to its Schedule 1 classification, Plandaí's interest in using the drug to discover promising treatments may be about to come to fruition. The company may owe this unexpected opportunity to relationships it has formed on an entirely different continent.
Plandaí has its principle holdings which consist of land, farms and infrastructure, and total more than 8500 acres, in the province of Mpumalanga, South Africa. The company's estate and factory in South Africa are set up to exclusively process its Phytofareâ„¢ Catechin Complex made from the green tea grown on the land there. Because South African law prohibits the cultivation of cannabis, the topic can be just as tricky there as it is here in the US, but legislators in that country may be a bit more open to facts than Washington, DC has been to date.
And, in support of this belief, a request for ministerial dispensation or a "waiver" was recently submitted on Plandaí's behalf by Dr. Mario Oriani-Ambrosini to the Secretary of Parliament of South Africa. If granted this waiver would permit Plandaí to conduct cannabis research in that country for medicinal purposes.
Dr. Oriani-Ambrosini is a South African legislator battling terminal cancer who recently introduced legislation to permit medical marijuana research and usage that has generated a groundswell of popular support and led to the formation of the Cancer Treatment Campaign. So together, Plandaí, Dr. Oriani-Ambrosini and the Cancer Treatment Campaign have requested a "waiver" that will allow Plandaí to produce and test a cannabinoid Phytofareâ„¢ extract for human clinical trials.
The significance of this waiver should it be granted would be that Plandaí could conduct its medicinal marijuana research from South Africa while the US continues to sort out its own laws pertaining to the drug, and its approval could expedite the company's efforts dramatically.
About Stock Market Media Group
SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. SMMG is compensated for Plandaí articles, reports and interviews by a third party who reserves the right to buy, sell or remain neutral on securities at any time before, during, or after the publication of this article. To date, SMMG has received total compensation of $39,190, for content related to Plandaí. For more information and to read full disclaimers and disclosures: www.stockmarketmediagroup.com/disclaimer.
Contact:
Stock Market Media Group
Email Contact
Plandai Biotechnology "Waiver" Could Dramatically Expedite Medical Marijuana Research
NEW YORK, NY--(Marketwired - Mar 31, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) has a real opportunity to advance its medical marijuana research, and in doing so, it could be one of the first publicly traded companies in the cannabis industry to reach clinical trials with the drug. While laws in the US still prohibit the advancement of research using marijuana due to its Schedule 1 classification, Plandaí's interest in using the drug to discover promising treatments may be about to come to fruition. The company may owe this unexpected opportunity to relationships it has formed on an entirely different continent.
Plandaí has its principle holdings which consist of land, farms and infrastructure, and total more than 8500 acres, in the province of Mpumalanga, South Africa. The company's estate and factory in South Africa are set up to exclusively process its Phytofareâ„¢ Catechin Complex made from the green tea grown on the land there. Because South African law prohibits the cultivation of cannabis, the topic can be just as tricky there as it is here in the US, but legislators in that country may be a bit more open to facts than Washington, DC has been to date.
And, in support of this belief, a request for ministerial dispensation or a "waiver" was recently submitted on Plandaí's behalf by Dr. Mario Oriani-Ambrosini to the Secretary of Parliament of South Africa. If granted this waiver would permit Plandaí to conduct cannabis research in that country for medicinal purposes.
Dr. Oriani-Ambrosini is a South African legislator battling terminal cancer who recently introduced legislation to permit medical marijuana research and usage that has generated a groundswell of popular support and led to the formation of the Cancer Treatment Campaign. So together, Plandaí, Dr. Oriani-Ambrosini and the Cancer Treatment Campaign have requested a "waiver" that will allow Plandaí to produce and test a cannabinoid Phytofareâ„¢ extract for human clinical trials.
The significance of this waiver should it be granted would be that Plandaí could conduct its medicinal marijuana research from South Africa while the US continues to sort out its own laws pertaining to the drug, and its approval could expedite the company's efforts dramatically.
About Stock Market Media Group
SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. SMMG is compensated for Plandaí articles, reports and interviews by a third party who reserves the right to buy, sell or remain neutral on securities at any time before, during, or after the publication of this article. To date, SMMG has received total compensation of $39,190, for content related to Plandaí. For more information and to read full disclaimers and disclosures: www.stockmarketmediagroup.com/disclaimer.
Contact:
Stock Market Media Group
Email Contact
GM homie-g !! PLPL going to kick butt today !!
I think today is going to be huge for PLPL. It's again due for a huge bounce if it stays true to the past few weeks !
Good morning PLPL !!
PLPL on High ALERT this week...look for this to move after a big dip and consolidation !!
PLPL on High ALERT this week...look for this to move after a big dip and consolidation !!
Good morning Everyone !!
Again, a nice time to load PLPL !
I think it was a good move, PLPL will swing back today, watch !!Good luck trading !
PLPL NEWS ! Plandai Biotechnology Management Discusses Progress of Company's Cannabis Extracts
2014-03-28 09:00 ET - News Release
NEW YORK, NY -- (Marketwired) -- 03/28/14
Last month Plandaí Biotechnology, Inc. (OTCQB: PLPL) closed a licensing agreement with Diego Pellicer, Inc. that will allow the company to use the Diego Pellicer name for its Phytofare? cannabis extract in medical and pharmaceutical marijuana applications. Plandaí will produce the new Diego Pellicer Gold? extracts in both capsules and cannabis oil (for vapor use) in Pheroid? and non-Pheroid? versions to appeal to the broadest range of medicinal consumers.
Stock Market Media Group (SMMG), a full service research and content development investor relations firm, asked Plandaí's management about the company's journey to introduce cannabis extracts to the market.
SMMG: Where is Plandai in the process of adding cannabis products?
Plandaí: "We are doing several things simultaneously. First, we're reviewing the various strains of cannabis and selecting one that we feel will have the best chemical profile for what we want to accomplish with the extract.
We're also working in Washington to ensure that we have live plant matter available for testing later in the year. Finally, we are engineering a CRS hydrodynamic processing and extraction system and constructing a laboratory in Washington that will make the initial extract for testing."
SMMG: What has been completed in the process and what is left to complete?
Plandaí: "The initial steps involved determining if we could even make a cannabis extract. This involved a review of the legal environment, the physical properties of the plant, and the chemical properties of the plant. We then needed to hire a small team that could 1) Select the correct strain, 2) Establish cultivation protocols, 3) Reach out to investigational institutions to begin lining up clinical trials, and 4) Adapt our current extraction system to be able to process cannabis. All of these things have happened.
We expect to finalize terms with a cultivation facility in the coming weeks so that we have suitable established plants in adequate quantities by this fall to begin making sample extract. Remember, we must use live plant material and we must use a specific and reproducible strain. We can't just go into a shop and buy dry leaf. Working with local growers, we need to document their cultivation techniques, fertilizer, etc. All of these things can impact the chemical profile. So, we need to manage the process to ensure that we have the correct chemical profile.
Concurrently, we will be building a small-scale lab so that we can produce our first cannabinoid extract. This will then need to be tested to get a chemical profile. We then need to test it for bioavailability and establish dosage parameters. Only then can we start testing for specific medical properties and benefits."
SMMG: What role will both the hydrodynamic sheering process and Pheroid® play in the production of extracts?
Plandaí: "The hydrodynamic sheering process is what breaks down and separates the plant structures, giving us increased bioavailability as well as allowing us to maximize the amount of phytonutrients we extract. All of our products will go through this process. The specific processing challenges we face with cannabis are releasing THC and CBD from the viscous cannabis oil and in the process reducing the articles to a high percentage of nano from the current ratio of 250-350mg. To achieve this, new formulated liquids will be used in the processing cycle.
The Pheroid® brings in certain additional properties which, depending on the individual may be considered advantageous or disadvantageous.
Essentially, the Pheroid® will entrap the cannabinoids until they reach the cells. This means that the THC will not metabolize in the blood stream, thus conceivably eliminating the psychoactive effects. We believe that we will be able to deliver a meaningful dosage of cannabinoids without the accompanying 'high.'
This will be ideal for patients with neural disorders and diseases. Some conditions require or prefer the metabolized THC and welcome the associated psychoactive effects. Thus, we expect to develop and test both a Pheroid® and non-Pheroid® version of the product."
SMMG: Where will these extracts be sold?
Plandaí: "We do not plan on having retail locations or selling directly to consumers. We are an ingredient manufacturer for nutraceutical and pharmaceutical applications. We will produce our extracts and then look to sell them to manufacturers of finished goods or into medicinal applications."
SMMG: What role, if any, will your South African plantation and manufacturing facility play in the future of your cannabis extract?
Plandaí: "Presently, South African law prohibits the cultivation of cannabis and furthermore it would be impossible to legally export or import any cannabis-based products or extracts. Our South Africa estate and factory is set up exclusively for processing our Phytofare? Catechin Complex, which is made from green tea, though eventually we expect to also produce a citrus complex at this same facility. So, our South Africa operations will not be involved in any way for the foreseeable future. Until we are through with our research and animal trials, it is premature to speculate on when, if, or where we will produce a commercial cannabis extract, but we will only be involved if we can be assured that we are complying with all Federal and state laws.
As we recently announced, however, an appeal was made on our behalf to the South African legislature to grant Plandaí a special dispensation, or waiver, allowing us to produce and test a cannabinoid Phytofare? extract for human clinical trials. In addition, legislation has recently been introduced in South Africa to permit medical marijuana research. Should this legislation pass, or should the government grant us special dispensation, it could open up the door to advancing medical research on an accelerated basis. We will know more in the coming months and will keep our shareholders apprised of any developments on this front."
About Stock Market Media Group
SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. SMMG is compensated for Plandaí articles, reports and interviews by a third party who reserves the right to sell securities at any time before, during, or after the publication of this article. To date, SMMG has received total compensation of $36,290, for content related to Plandaí. For more information and to read full disclaimers and disclosures: www.stockmarketmediagroup.com/disclaimer.
Add to DiggBookmark with del.icio.usAdd to Newsvine
Contact:
Stock Market Media Group
Email Contact
Good morning PLPL !
PLPL on high Alert !! looking to close out a Friday with some big gains. Great swing play !!
Good morning everyone !
$POIL shooting for that eod run !!
Looks like $POIL wants to break out !!